$RENE #ReNeuron Group ReNeuron Group - Focus on retinal therapy, out-licensing of stroke: ReNeuron has changed its focus to concentrate on cell therapy for retinal disorders. The Phase I/II has FDA clearance to use a higher dose and a new… https://t.co/XD9aRg1RYm #equity #stocks https://t.co/GqhPpfWnCU